Read about our top 10 most read MS articles of , covering results of and clinical trials related to multiple sclerosis (MS) throughout Although multiple sclerosis (MS) is more likely to be diagnosed in adults between the ages of 20 and 40, children can also develop the. Top 10 Multiple Sclerosis Studies of SPT Staff. Publish Date: Monday, December 24, From clinical trials evaluating treatments to studies unearthing.
Sclerosis 10) Multiple
Researchers have long suspected that a self-antigen—a normal molecule in the body that the immune system mistakenly treats as a threat—can trigger MS.
The prime suspects have been proteins in myelin, the nerve insulation that erodes in patients with the disease. To uncover other candidates, immunologists Roland Martin and Mireia Sospedra of University Hospital of Zurich in Switzerland and their colleagues analyzed immune cells known as T cells that came from a patient who died from MS. T cells normally switch on when they encounter protein fragments containing just a few amino acids that belong to an invading microbe, but they also turn on in people who have MS.
The two fragments with the strongest effect turned out to be part of a human enzyme called guanosine diphosphate-L-fucose synthase, which helps cells remodel sugars that are involved in everything from laying down memories to determining our blood type.
If guanosine diphosphate-L-fucose synthase turns out to be one of the elusive MS self-antigens, dosing patients with it might tame symptoms such as numbness and muscle weakness in much the same way that allergy shots prevent people from reacting to substances like ragweed pollen, Sospedra says. She and her colleagues plan to start to test this strategy with MS patients next year. Analyses of correlations between clinical variables and cognitive deficits have up to now yielded conflicting findings.
This suggests that, as the illness advances, neurological and cognitive deficits tend to converge. Similarly, in the article by Comi et al, 45 the onset of secondary progression after a relapsing-remitting phase is identified as a crucial event in the appearance and development of cognitive dysfunction.
Age-related memory decline is well documented in the literature as a demographic predictor. Finally, few authors have specifically assessed the effect of cognitive impairment on everyday life of patients with MS. In conclusion, these results point to cognitive impairment as a common element in the natural history of MS that cannot be ignored. While present at times from the disease's earliest phases, only in the course of a sufficiently long follow-up is such dysfunction likely to emerge and progress in a sizable proportion of patients, although at different rates and with varying degrees of severity.
Moreover, cognitive problems, together with neurological disability, constitute the principal determinants of a patient's handicap. In the past few years, new therapies have been approved for patients with the relapsing-remitting form of MS.
These therapies have proven to be effective in reducing the frequency of relapses and in limiting activity parameters as well as the cerebral lesion load on magnetic resonance scans. We thank Eda Berger Vidale, PhD, for her assistance in translating and editing the manuscript, Laura Bracco, MD for her assistance in interpreting neuropsychological findings, and Vieri Boddi, MS, for his assistance in the statistical analysis.
Multiple Linear Regression Analysis: Clinical and Pathogenetic Basis. J Nerv Ment Dis. J Consult Clin Psychol. J Neurol Neurosurg Psychiatry. Br J Clin Psychol. Br J Soc Clin Psychol. Int J Geriatr Psychiatry.
Purchase access Subscribe to the journal. Get free access to newly published articles. Create a personal account to register for email alerts with links to free full-text articles. Purchase access Subscribe to JN Learning for one year. Sign in to download free article PDFs Sign in to access your subscriptions Sign in to your personal account. Get free access to newly published articles Create a personal account or sign in to: Register for email alerts with links to free full-text articles Access PDFs of free articles Manage your interests Save searches and receive search alerts.
Sign in to save your search Sign in to your personal account. Create a free personal account to access your subscriptions, sign up for alerts, and more. Purchase access Subscribe now. Archived from the original on 7 July Four disease courses have been identified in multiple sclerosis: The clinical neuropsychiatry of multiple sclerosis 2nd ed. Disease-modifying therapies for adults with multiple sclerosis".
The Cochrane Database of Systematic Reviews. Royal College of Physicians. Retrieved 6 February Archived from the original on 30 January Retrieved 22 September Archived from the original on 12 May Retrieved 4 June Biogen Idec Press Release. Archived from the original on 19 November Archived from the original on 3 April Current Neurology and Neuroscience Reports. Archived from the original on 1 April Archived PDF from the original on 1 April Retrieved 1 April Archived PDF from the original on 2 April Expert Opinion on Drug Safety.
Kellerman 22 December Conn's Current Therapy Expert Consult — Online and Print. The efficacy and safety of mitoxantrone Novantrone in the treatment of multiple sclerosis: The Cochrane Database of Systematic Reviews 5: US Food and Drug Agency. Retrieved 5 April Annals of the New York Academy of Sciences. The Cochrane Database of Systematic Reviews 2: The Cochrane Database of Systematic Reviews 3: The Cochrane Database of Systematic Reviews 1: A systematic review and meta-analysis".
Journal of Psychosomatic Research. The Journal of Biological Chemistry. Archived from the original on 24 October Archived from the original on 16 February Journal of Neurology, Neurosurgery, and Psychiatry.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. The Journal of a Disappointed Man. Archived from the original on 17 September Retrieved 21 May Archived from the original on 4 October Expert Review of Neurotherapeutics. Popescu, Istvan Pirko, Claudia F. Lucchinetti, Pathology of Multiple Sclerosis: Where Do We Stand? European Journal of Neurology. Novel therapeutic options and drug targets in MS". Archived from the original on 4 August Journal of NeuroInterventional Surgery.
Pathophysiology Experimental autoimmune encephalomyelitis Multiple sclerosis drug pipeline Multiple sclerosis research. List of people with multiple sclerosis List of multiple sclerosis organizations. Encephalitis Viral encephalitis Herpesviral encephalitis Limbic encephalitis Encephalitis lethargica Cavernous sinus thrombosis Brain abscess Amoebic.
Poliomyelitis Demyelinating disease Transverse myelitis Tropical spastic paraparesis Epidural abscess. Encephalomyelitis Acute disseminated Myalgic Meningoencephalitis. Focal Generalised Status epilepticus Myoclonic epilepsy. Migraine Familial hemiplegic Cluster Tension. Insomnia Hypersomnia Sleep apnea Obstructive Congenital central hypoventilation syndrome Narcolepsy Cataplexy Kleine—Levin Circadian rhythm sleep disorder Advanced sleep phase disorder Delayed sleep phase disorder Nonhour sleep—wake disorder Jet lag.
Brain herniation Reye's Hepatic encephalopathy Toxic encephalopathy Hashimoto's encephalopathy. Hypersensitivity and autoimmune diseases Atopic eczema Allergic urticaria Allergic rhinitis Hay fever Allergic asthma Anaphylaxis Food allergy common allergies include: Hemolytic disease of the newborn.
Graves' disease Myasthenia gravis Pernicious anemia. Systemic lupus erythematosus Subacute bacterial endocarditis Rheumatoid arthritis. Allergic contact dermatitis Mantoux test.
Diabetes mellitus type 1 Hashimoto's thyroiditis Multiple sclerosis Coeliac disease Giant-cell arteritis Postorgasmic illness syndrome Reactive arthritis. Transfusion-associated graft versus host disease. Retrieved from " https: Multiple sclerosis Epstein—Barr virus-associated diseases Ailments of unknown cause. Views Read View source View history.
In other projects Wikimedia Commons.
The 10 Multiple Sclerosis Blogs We Can’t Stop Reading
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells Life expectancy is on average 5 to 10 years lower than that of an unaffected population. Multiple sclerosis is the most common immune-mediated. Multiple sclerosis (MS) is an incurable autoimmune disease that can put an end to careers, daily activities, and even relationships. For rougher. Multiple Sclerosis Top Which treatments are effective to slow, stop or reverse the accumulation of disability associated with MS? How can MS be prevented?.